ZELIRA THERAPEUTICS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.71 AUD | +1.43% |
|
0.00% | -21.11% |
| Sales 2022 | 1.54M 1.01M | Sales 2023 | 301K 197K | Capitalization | 17.13M 11.18M |
|---|---|---|---|---|---|
| Net income 2022 | -11M -7.18M | Net income 2023 | -5M -3.26M | EV / Sales 2022 | 4.57 x |
| Net cash position 2022 | 2.25M 1.47M | Net Debt 2023 | 292K 190K | EV / Sales 2023 | 57.9 x |
| P/E ratio 2022 |
-0.65
x | P/E ratio 2023 |
-2.73
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 51.29% |
More Fundamentals
* Assessed data
More news
Latest transcript on Zelira Therapeutics Limited
More press releases
| 1 day | +1.43% | ||
| Current month | +1.43% | ||
| 1 month | +1.43% | ||
| 3 months | -18.39% | ||
| 6 months | -22.83% | ||
| Current year | -21.11% |
1 week
0.69
0.72
1 month
0.680.75
Current year
0.680.95
1 year
0.683.35
3 years
0.6810.68
5 years
0.6824.50
10 years
0.6828.00
| Managers | Title | Age | Since |
|---|---|---|---|
Oludare Odumosu
CEO | Chief Executive Officer | - | 19-11-27 |
Rahul Ganesan
DFI | Director of Finance/CFO | - | - |
Greg Blake
BRD | Director/Board Member | - | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Osagie Imasogie
CHM | Chairman | 62 | 19-11-27 |
Timothy Slate
BRD | Director/Board Member | - | 16-10-19 |
Oludare Odumosu
CEO | Chief Executive Officer | - | 19-11-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 0.71 | +1.43% | 1 279 |
| 24-04-23 | 0.7 | +1.45% | 174 |
| 24-04-22 | 0.69 | -2.82% | 490 |
| 24-04-19 | 0.71 | -1.39% | 3,894 |
| 24-04-18 | 0.72 | +1.41% | 6,518 |
Delayed Quote Australian S.E., April 23, 2024 at 09:43 pm EDT
More quotes
Zelira Therapeutics Limited is an Australia-based biopharmaceutical company. The Company is engaged in the research, development and commercialization of clinically validated cannabinoid-based medicines. It owns a portfolio of products and a pipeline of candidates undergoing clinical development positioned to enter global markets. It is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription [Rx] business for the treatment of a variety of medical conditions, including insomnia, autism and chronic non-cancer pain, as well as offering over the counter [OTC] products. It has two medications: HOPE and ZENIVOL. ZENIVOL is a cannabinoid-based medicine for the treatment of chronic insomnia. The Company in partnership with SprinJeneCBD, introduced a full line of oral care products, including SprinJeneCBD toothpaste product, which is a hemp-derived, oral care products containing cannabinoids, blackseed oil and zinc utilizing patented technology.
Calendar
2024-08-28
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.11% | 5.04M | |
| -0.49% | 103B | |
| +3.31% | 96.73B | |
| +1.66% | 21.31B | |
| -16.16% | 21.21B | |
| -6.82% | 18.79B | |
| -41.41% | 16.37B | |
| -22.87% | 13.68B | |
| +6.32% | 13.44B | |
| +21.46% | 10.98B |
- Stock Market
- Equities
- ZLD Stock
